Laboratoire Dazont has been acquired by SBM Company
The shareholders of Laboratoire Dazont have sold the company to SBM Company.
Created in 2008, Laboratoire Dazont is a France-based company specialized in the design, manufacture and distribution of natural veterinary solutions for pharmacies and parapharmacies. The company offers a complete range of approximately 50 references of natural products, including aromatherapy, petcare, and products and food supplements for dogs and cats under the Vetoform and Vetonut brands. Laboratoire Dazont offers its solutions to 750 pharmacies and parapharmacies in France, including key accounts such as E. Leclerc and Santédiscount.
Created in 1994, SBM Company is a family-owned French group with presence in more than 31 countries throughout Europe and North America. SBM designs, homologates, produces and markets products for the care and protection of crops, gardens and homes. In 2021, the group generated approximately US$360 million in sales, 60% internationally.
Oaklins’ team in France acted as M&A advisor to Laboratoire Dazont in the disposal of the company to SBM Company.
Talk to the deal team
Related deals
Vivo Diagnóstico has been acquired by NEXXUS-IBERIA SGEIC, S.A.
NEXXUS-IBERIA SGEIC, S.A. a private equity firm in Spain, has completed its acquisition of a majority stake in Vivo Diagnóstico. With this financial backing from NEXXUS-IBERIA, Vivo will focus on inorganic growth as well as investing in service quality, innovation and efficiency.
Learn moreCreo Medical Group plc has completed a US$15.7 million equity fundraise
Creo Medical Group plc, the provider of pioneering endoscopic healthcare solutions to clinicians and healthcare providers across the world, has completed a US$15.7 million (£12.1 million) equity fundraise.
Learn moreHD Clinical Ltd. has been acquired by NEXUS AG
NEXUS AG has acquired HD Clinical Ltd. Through this acquisition, NEXUS has gained a recognized and internationally active team of experts in structured diagnostic reporting and image processing. This will provide new regional access, strengthening its strong European market position in software, particularly for internal medicine.
Learn more